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T lymphocytes exhibit pro-inﬂammatory or anti-inﬂammatory activities in
obesity and diabetes, depending on their subtypes. Guanidine-rich immunosup-
pressive oligodeoxynucleotides (ODNs) effectively control Th1/Th2-cell counter-
balance. This study reveals a non-toxic regulatory ODN (ODNR01) that inhibits
Th1- and Th17-cell polarization by binding to STAT1/3/4 and blocking their
phosphorylation without affecting Th2 and regulatory T cells. ODNR01 improves
glucose tolerance and insulin sensitivity in both diet-induced obese (DIO) and
geneticallygeneratedobese(ob/ob)mice.MechanisticstudiesshowthatODNR01
suppresses Th1- and Th17-cell differentiation in white adipose tissue, thereby
reducingmacrophageaccumulationandM1macrophageinﬂammatorymolecule
expression without affecting M2 macrophages. While ODNR01 shows no effect
on diabetes in lymphocyte-free Rag1-deﬁcient DIO mice, it enhances glucose
tolerance and insulin sensitivity in CD4
þ T-cell-reconstituted Rag1-deﬁcient DIO
mice, suggesting its beneﬁcial effect on insulin resistance is T-cell-dependent.
Therefore, regulatory ODNR01 reduces obesity-associated insulin resistance
through modulation of T-cell differentiation.
INTRODUCTION
Obesity and diabetes involve chronic inﬂammation (Hotamisli-
gil, 2006). Recent studies in humans and animals have
demonstrated that in addition to adipocytes, white adipose
tissue (WAT) in obese subjects contains macrophages, mast
cells and several different T-cell subsets (Caspar-Bauguil et al,
2005; Liu et al, 2009; Lumeng et al, 2009; Weisberg et al, 2003).
These pro-inﬂammatory cells populate the stromal vascular
fraction (SVF) of fat tissue where they produce inﬂammatory
cytokines, proteases, growth factors and chemokines that
modulate numerous WAT functions (Lago et al, 2007). Upon
encountering antigenic peptides from antigen-presenting cells
(APCs), CD4
þ T cells polarize into different lineages, including
T helper 1 (Th1), Th2, Th17 and regulatory T cells (Treg), as
deﬁned by their pattern of functions and cytokine proﬁles
(Zhu et al, 2010). Recent studies have demonstrated an
imbalance between dominant Th1 responses and reduced
Th2 or Treg responses in WAT from obese subjects (Feuerer
et al, 2009; Nishimura et al, 2009; Winer et al, 2009a). Enhanced
Th1 cells in WAT produce interferon-g (IFN-g) leading to
increased recruitment of adipose tissue macrophages (ATMs)
and a shift in the activation state of ATMs from a protective
alternatively activated (M2) state to a classically activated (M1)
pro-inﬂammatory phenotype (Feuerer et al, 2009; Nishimura
et al, 2009; Rocha et al, 2008; Winer et al, 2009a).
DNA exerts complex effects on the immune system,
depending on its sequence. Bacterial DNA or synthetic
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unmethylated CpG dinucleotides can stimulate immune
responses in both Toll-like receptor 9 (TLR9)-dependent and
TLR9-independent pathways (Krieg, 2002; Krieg et al, 1995;
Landrigan et al, 2011), leading to the activation of macrophages,
dendritic cells as well as B cells and the differentiation of Th1
and cytotoxic T cells. This class of ODNs can stimulate innate
immune responses to heighten host resistance to infectious
microorganisms and tumours, and to augment antigen pre-
sentation and facilitate the development of adaptive immune
responses. Several ongoing clinical trials have examined the
efﬁcacy of such ODNs among patients with allergies, auto-
immune diseases and cancers (Fonseca and Kline, 2009;
Manegold et al, 2008; Schmidt, 2007). Unlike such immuno-
stimulatory ODNs, regulatory ODNs mimic the immunosup-
pressive activity of the repetitive TTAGGG motifs present in
mammalian telomeres, and can block the production of pro-
inﬂammatory and Th1 cytokines triggered by polyclonal
activators and antigens (Shirota et al, 2004; Gursel et al,
2003). In contrast, regulatory ODNs act by selectively binding to
STAT1 and STAT4, then blocking their subsequent phosphor-
ylation—and these activities do not require binding to receptors
such as TLR9 (Shirota et al, 2004, 2005). In animals, regulatory
ODNs can effectively ameliorate several Th1-biased autoim-
mune diseases, such as experimental autoimmune encephalo-
myelitis (EAE), arthritis and atherosclerosis (Zeuner et al, 2002,
2003; Cheng et al, 2008).
This study generated and evaluated several guanidine-rich
ODNs and identiﬁed one regulatory ODN—termed regulatory
ODNR01—that suppressed Th1 and Th17 differentiation more
effectively and selectively than did previously described
immunosuppressive ODNs. ODNR01 bound selectively to
STAT1/3/4 and blocked their phosphorylation, limiting Th1
and Th17-cell differentiation. Peritoneal administration of
ODNR01, but not of non-speciﬁc ODN1612, to diet-induced
obese (DIO) C57BL/6 mice or genetically generated obese
diabetic (ob/ob) mice muted the manifestations of type-2
diabetes, which required T cells.
RESULTS
Role of ODNR01 in suppressing Th1 and Th17 differentiation
To develop novel immunosuppressive ODNs, we designed four
regulatory ODNs by changing the deoxynucleotides preceding
the poly(G) motif. We used the most effective known
immunosuppressive, ODNA151 (Klinman et al, 2008; Shirota
etal,2005),asapositivecontroltoexaminewhetherthesenovel
regulatory ODNs effectively regulated T-cell differentiation.
Peripheral CD4
þ T cells from 8-week-old, Th1-biased C57BL/
6 wild-type (WT) mice were cultured under different T-cell
differentiation conditions (Th0, Th1 and Th17) in the presence
of different ODNs (5mM) as well as anti-mouse CD3 and anti-
mouse CD28 monoclonal antibodies (mAbs). Enzyme-linked
immunosorbent assay (ELISA) showed that, under Th0
conditions (no additives), three of four regulatory ODNs
(ODNR01, ODNR03 and ODNR04) and ODNA151 signiﬁcantly
decreased IFN-g and IL-17 production detectable in the culture
media, but showed negligible effects in inhibiting IL-4 produc-
tion. Among all effective ODNs, ODNR01 showed the most
potent inhibition of IFN-g and IL-17 production (Fig 1A). To
explore further the effect of regulatory ODNs on T-cell
differentiation, we repeated these studies in Th1 (IL-12
and anti-IL-4) and Th17 (IL-6, TGF-b, IL-23, anti-IFN-g and
anti-IL-4) culture conditions, which allowed Th1 and Th17
differentiation, respectively (Cui et al, 2009). Yet even under the
Th1 and Th17 culture conditions, three regulatory ODNs and
immunosuppressive ODNA151 signiﬁcantly decreased IFN-g
(Th1) and IL-17 (Th17) production, and ODNR01 retained
considerable inhibitory activities (Fig 1A). Under all conditions,
the non-speciﬁc ODN1612 did not affect any of the cytokines
tested.
Because regulatory ODNR01 comprising tandem TAGGG
motifs showed the most immunosuppressive ability on Th1 and
Th17 differentiation among all four novel regulatory ODNs and
the known immunosuppressive ODNA151, we tested the
concentration-dependence of ODNR01 on inhibition of Th1
(IFN-g), Th2 (IL-4) and Th17 (IL-17) cytokine production under
three T-cell differentiation conditions. Incubation of ODNR01
with CD4
þ T cells under Th0, Th1 and Th17 culture conditions
resulted in a concentration-dependent decrease of IFN-g and IL-
17 production in the medium as determined by ELISA (Fig 1B).
Under the same conditions, ODNR01 lacked effect on IL-4
production at any tested concentration, suggesting preferential
inhibition of ODNR01 on differentiation of Th1 and Th17, but
not of Th2. Real-time polymerase chain reaction (RT-PCR)
analysis of cytokine mRNA levels yielded the same conclusion.
ODNR01 (5–10mM) inhibited IFN-g and IL-17 expression
signiﬁcantly, but not that of IL-4 (Fig 1C). Flow cytometry
histogram analysis further showed that ODNR01 inhibits
Th1- and Th17-cell differentiation, but not Th2- or Treg-
differentiation. When puriﬁed CD4
þ T cells were cultured
under Th0, Th1 and Th17 conditions, followed by intracellular
staining with anti-T-bet and anti-RORgt antibodies to detect
Th1- and Th17-cell populations (Cui et al, 2009; Yang et al,
2008), we found that under Th0 conditions, 5 10mMo f
ODNR01 reduced the percentage of Th1 and Th17 cells.
Under Th1 and Th17 conditions, 5 10mM of ODNR01
inhibited the percentages of Th1 cells and Th17 cells
signiﬁcantly (Fig 1D and E). ODNR01 at any tested concentra-
tion, however, did not affect Th2 cells or CD4
þCD25
þFoxp3
þ
Treg frequency (Supporting Information Fig 1). At the
same concentration (5mM), ODNR01 was signiﬁcantly
stronger than ODNA151 in inhibiting the expression of IFN-g
and IL-17 or Th1 and Th17-cell frequencies, but had no
inhibitory effect on IL-4 expression or Th2-cell frequencies in
peripheral CD4
þ T cells from Th1-biased C57BL/6 mice, while
the control ODN1612 had no inhibitory activity (Supporting
Information Fig 2A and B).
Splenic CD4
þ T cells from Th2-biased Balb/c mice behaved
similarly to those from Th1-biased C57BL/6 mice, which have
constitutively suppressed Th2 responses (Bix et al, 1998). ELISA
and RT-PCR determined that ODNR01 suppressed IFN-g and
IL-17 production dose-dependently at both protein and mRNA
www.embomolmed.org Research Article
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þ T cells from Balb/c mice under all three T-cell
differentiation conditions (Th0, Th1 and Th17). At the same
concentrations (1 10mM), however, ODNR01 did not affect
IL-4 production at the protein and mRNA level (Supporting
Information Fig 3A and B).
ODNR01 binds to STAT1/3/4 and blocks phosphorylation
To understand the mechanisms by which ODNR01 suppresses
Th1 and Th17 differentiation, but not Th2 or Treg, we examined
the STAT signalling pathways that direct T-cell subset
differentiation and expansion (Zhu et al, 2010). IFN-g
(0.5ng/ml)and IL-12 (0.5ng/ml)stimulate thephosphorylation
of STAT1 and STAT3/4, respectively (Afkarian et al, 2002;
Harris et al, 2007; Thierfelder et al, 1996). While non-speciﬁc
ODN1612 showed no effect on the phosphorylation of these
STATs, 5mM of ODNA151 and ODNR01 greatly inhibited the
phosphorylation of STAT1 and STAT3/4 (Fig 2A). Under the
same experimental conditions, ODNR01 appeared much more
potent than ODNA151 in suppressing STAT1/3/4 phosphoryla-
tion (Fig 2A). IL-2 (10ng/ml) and IL-4 (10ng/ml) are commonly
used to activate STAT5 and STAT6, which are critical to the
differentiation of Treg and Th2, respectively (Burchill et al,
2007; Kaplan et al, 1996). Neither ODN1612 nor ODNA151 or
ODNR01 inhibited STAT5 or STAT6 phosphorylation (Fig 2B),
suggesting that ODNR01—but not ODN1612—inhibited the
differentiation of Th1 and Th17 cells even more strongly than
the known ODNA151, but not the differentiation of Treg or Th2
cells.
Inhibition of the phosphorylation of STAT1/3/4, but not of
STAT5/6, by ODNR01, but not by ODN1612, suggested direct
interaction of ODNR01 with cytoplasmic STAT1/3/4, but not
with other STATs. To test this possibility, we performed
confocal microscopy to monitor ODNR01–STAT interactions in
cultured peripheral CD4
þ T cells. In CD4
þ T cells treated with
ODNR01, ODNR01 (green) co-localized with STAT1/3/4 (red),
but not with STAT5/6 (red; Fig 2C). In contrast, none of these
STATs co-localized with the non-speciﬁc ODN1612 (green).
Direct interaction between ODNR01 and STAT1/3/4 was
explored using biotinylated ODNs in live CD4
þ T cells and in
CD4
þ T-cell lysates. Avidin-coated agarose beads bound
Research Article www.embomolmed.org
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Figure 1. Immunosuppressive activity of ODNR01 on Th1- and Th17-cell differentiation.
A. CD4
þT-cell culturemediaIFN-g,IL-4andIL-17 levelsasdeterminedbyELISA.CD4
þTcellsweretreated withanti-CD3 andanti-CD28mAbwithor without ( )
5mM ofthedifferent regulatory ODNs underTh0, Th1 orTh17conditionsfor 3days.Immunosuppressive ODNA151 wasusedas apositive control,and random
ODN1612 was used as a negative control.
 p<0.05 versus ( ) and ODN1612; #p<0.05 versus ODNA151.
B. ELISA determined CD4
þ T-cell culture media IFN-g, IL-4 and IL-17 levels after cells were cultured with or without ODN1612(5mM) and different doses of
ODNR01 (1, 5 and 10mM) under Th0, Th1 or Th17 conditions.
 p<0.05 versus ( ) and ODN1612.
C. RT-PCR determined CD4
þ T-cell IFN-g, IL-4 and IL-17 mRNA levels after cells were treated as in B.
 p<0.05 versus ( ) and ODN1612.
D. Representative FACS histograms of Th1 and Th17 cells for purified CD4
þ T cells treated under Th0, Th1 or Th17 conditions with or without ODN (5mM) for
4 days. Lymphocytes were first gated on the SSC/FSC plots and then the expression of T-bet and RORgt on the purified CD4
þ T cells was analyzed.
E. Th1- or Th17-cell frequencies in CD4
þ T cells after cells were treated with ODNs as in B for 4 days,
 p<0.05 versus ( ) and ODN1612. Data are representative
of three independent experiments.
1114  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2012) 4, 1112–1125complexes of biotin-ODNR01 with STAT1/3/4, but not with
STAT5/6 from live CD4
þ T cells. Incubating biotin-ODNR01
with CD4
þ T cells, followed by binding whole-cell lysate
onto avidin-coated agarose beads, showed increased binding
of STAT1/3/4, but not of STAT5/6 in the eluate from the
avidin beads, as detected by subsequent immunoblot analysis
using corresponding anti-STAT antibodies (Fig 2D, left panels).
In contrast, the same method did not detect any differences
between biotin-ODN1612-treated CD4
þ T cells and untreated
CD4
þ T cells (Fig 2D, left panels), suggesting direct interaction
between ODNR01 and STAT/1/3/4, but not among other tested
signalling molecules or non-speciﬁc ODN1612. In CD4
þ T-cell
lysates, biotin-ODNR01 (1mM) also bound to STAT1/3/4, an
interaction that was blocked by excess free ODNR01 (5mM), but
not by free ODN1612 (5mM; Fig 2D, right panel) further
demonstrating the interaction of ODNR01 and STAT1/3/4 in
CD4
þ T cells.
ODNR01 controls type-2 diabetes in obese mice
AlteredbalanceamongTh1,Th2andTregcontributesdirectlyto
obesity and diabetes. In WAT from DIO mice and ob/ob mice,
increased IFN-g–secreting Th1 and CD8
þ T cells are accom-
panied by reduced numbers of Th2 cells [CD4
þGATA-binding
protein-3 (GATA-3)
þ] and regulatory forkhead box P3 (Foxp3)
þ
Treg cells (Feuerer et al, 2009; Nishimura et al, 2009; Winer
et al, 2009a). While CD8
þ T cells control the inﬁltration of
macrophages and promote type-2 diabetes (Zhu et al, 2010),
CD4
þ T cells (presumably Th2 cells; Winer et al, 2009a,b)
and Treg (Feuerer et al, 2009) reverse obesity and/or type-2
diabetes. ODNR01-mediated blockage of Th1 and Th17
differentiation may interrupt the balance between pro-
inﬂammatory Th1/Th17 cells and anti-inﬂammatory Th2/Treg
cells, which may protect DIO mice and ob/ob mice from T-cell
inﬂammation-associated obesity and type-2 diabetes. Yet, we
found no signiﬁcant differences in body weight gain among
www.embomolmed.org Research Article
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Figure 2. Immunosuppression of STAT1/3/4 phosphorylation by ODNR01 selective binding.
A,B. STAT and phospho-STAT Western blot analysis of anti-CD3/28 mAb-stimulated CD4
þ T cells treated with indicated cytokines, with and without 5mMo f
ODNR01, ODNA151 or ODN1612.
C. Confocalmicroscopy todetectco-localization ofFITC-conjugatedODNs(2.5mM;green)withdifferentAlexFluor555-conjugated anti-STAT rabbitpolyclonal
antibodies (red) in CD4
þ T cells after 24h of incubation.
D. Left panels: Immunoblot analysis of STATs from CD4
þ T cells pre-incubated with 5mM biotinylated-ODNs, lysed, and precipitated with avidin agarose
beads for STAT detection. Right panels: Immunoblot analysis of STATs from CD4
þ T-cell lysates that were pre-incubated with 1mM biotinylated ODN and
5mM unlabelled ODN for 1h and immunoprecipitated with avidin beads for detection of different STAT. The experiments were repeated three times
with similar results.
EMBO Mol Med (2012) 4, 1112–1125  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1115the DIO groups or the ob/ob groups, regardless of whether
mice received regulatory ODNR01, non-speciﬁc ODN1612 or
phosphate buffered saline (PBS; Fig 3A). Consistent with
these observations, we detected no signiﬁcant differences in
serum total cholesterol, high-density cholesterol (HDL) and
triglyceride levels among these groups (Supporting Information
Fig 4). Both visceral adipose tissue (VAT) and subcutaneous
adipose tissue (SAT) fat mass, however, weighed about 0.3g
less in ODNR01-treated mice than in PBS-treated mice in both
the ob/ob and DIO groups (Fig 3B). ODNR01-induced reductions
in fat mass did not lead to signiﬁcant changes in body weight
gain from those of PBS- or ODN1612-treated mice (Fig 3A).
Further, ODNR01-treated ob/ob mice and DIO mice had smaller
adipocytes than controls (Fig 3C), suggesting that ODNR01
reduced WAT inﬂammation. Adipocyte size often associates
with plasma adiponectin production (Bahceci et al, 2007;
Skurk et al, 2007), but in our study, ODNRO1-induced
adipocyte size changes did not affect plasma adiponectin
levels (Supporting Information Fig 5). We also found that
intraperitoneal administration (once every 2 weeks) of
ODNR01, but not of ODN1612, signiﬁcantly reduced fasting
insulin levels in serum (Fig 3D) and improved glucose tolerance
as well as insulin sensitivity (Fig 3E) in both DIO mice and ob/ob
mice.Althoughwedidnotmonitormousefoodandwaterintake
due to insigniﬁcant body weight differences between the
groups (Fig 3A), histologic examination of liver or gastro-
intestinal tract did not show differences between the groups.
ODNR01, therefore, induced no discernable toxic effects and
mitigated obesity-associated type-2 diabetes, but not body
weight gain.
ODNR01 regulates CD4
R T-cell subsets in obese mice
CD4
þ T cells, including Th2 and Treg cells, effectively control
body weight gain and/or obesity-associated insulin sensitivity
in mice (Feuerer et al, 2009; Winer et al, 2009a,b). ODNR01
effectively inhibited Th1- and Th17-cell differentiation in vitro
but did not affect Th2 or Treg (Figs 1 and 2), leading to a shift in
balance toward Th2 and Treg and improved insulin sensitivity
in obese mice (Fig 3D and E). We examined T-cell subsets in
VAT, SAT and spleen from DIO mice (Fig 4). Flow cytometry
analysis of the SVF preparation from VAT of DIO mice
demonstrated that ODNR01 reduced CD4
þIFN-g
þ (Th1) and
CD4
þIL-17
þ (Th17) cells, but did not affect CD4
þIL-4
þ (Th2)
and CD4
þFoxp3
þ (Treg) cells (Fig 4A). In contrast, non-speciﬁc
ODN1612 did not affect any of these CD4
þ T-cell subsets. We
madesimilar observations in SAT and spleen from thesame DIO
mice (Fig 4B). Serum Th subset characteristic cytokines showed
similar regulation by ODNR01. Both serum Th1 cytokine IFN-g
and Th17 cytokine IL-17 levels were signiﬁcantly lower in
mice treated with ODNR01, but not with ODN1612, although
serum IL-4 levels were undetectable (Fig 4C). These results
suggest that ODNR01 regulates Th-cell subsets in vivo,
which may explain reduced glucose tolerance and enhanced
insulin sensitivity in DIO mice and ob/ob mice (Fig 3D and E).
Research Article www.embomolmed.org
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Figure 3. Effects of ODNs on obesity and diabetes in mice.
A. Bodyweight gain in DIO mice (ona high-fat diet, HFD) and ob/obmice (on anormal chow diet, NCD) treated with ODNR01, negativecontrol ODN1612 or PBS
for indicated weeks (one dose/2 weeks).
B-E. VAT and SAT fat mass (B), VAT adipocyte sizes (C), serum insulin levels (D), and glucose and insulin tolerance (E) from DIO mice and ob/ob mice at the end of
treatment.
 p<0.05,
  p<0.01, n¼7 8 mice per group.
1116  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2012) 4, 1112–1125To test this conclusion further, we isolated CD4
þ T cells
from DIO mice that were treated with ODNR01, ODN1612 or
PBS and examined the mRNA levels of different Th subset-
speciﬁc key transcription regulatory molecules. ODNR01
inhibited signiﬁcantly the mRNA levels of transcription
factor T-bet and orphan nuclear receptor RORgt—which are
Th1- and Th17-cell signature transcriptional regulators—in
VAT, SAT and spleen. Under the same conditions, ODNR01
did not affect the expression of transcription factor GATA-3
or transcription regulator Foxp3, both of which belong to
the Th2 and Treg cell-transcription machinery (Fig 4D).
Under all tested conditions, the non-speciﬁc ODN1612
did not affect any of these transcriptional regulators. Study
of CD4
þ T cells from VAT, SAT and spleen from ob/ob
mice yielded similar observations (Supporting Information
Fig 6).
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Figure 4. ODNR01 regulates CD4
R T-cell subsets in DIO mice.
A. Representative FACS plots of Th1, Th2, Th17 and Treg cells in VAT from DIO mice treated with different ODNs. CD4
þ T cells were first gated on the SSC/CD4
plots, and then the expression of IFN-g, IL-4, IL-17 and Foxp3 was analyzed in the gated CD4
þ T cells.
B. The frequencies of Th1, Th2, Th17 and Treg cells in VAT, SAT and spleen from DIO mice treated with different ODNs.
C. ELISA determined serum IFN-g, IL-4 and IL-17 concentrations in DIO mice treated with different ODNs.
D. RT-PCR determined mRNA levels of transcription regulators (T-bet, GATA-3, RORgt and Foxp3) in sorted CD4
þ T cells from VAT, SAT and spleen of DIO mice
treated with different ODNs.
 p<0.05,
  p<0.01, ND: not detectable, n¼6 8 mice per group.
EMBO Mol Med (2012) 4, 1112–1125  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1117ODNR01 reduces adipose tissue macrophage accumulation
and M1-associated inflammatory factor expression
WAT pro-inﬂammatory cells, such as CD8
þ T cells and mast
cells, directly inﬂuence macrophage accumulation, thereby
affecting adipose tissue growth, glucose metabolism and insulin
sensitivity (Liu et al, 2009; Nishimura et al, 2009). Reduced pro-
inﬂammatory Th1 and Th17 cells in ODNR01-treated DIO mice
or ob/ob mice may also result in low macrophage content
in WAT. VAT immunostaining with anti-Mac-3 mAb revealed
signiﬁcantly fewer Mac-3
þ cells in VAT from ODNR01-
treated DIO mice than in those from PBS-treated or
ODN1612-treated mice (Fig 5A). VAT from ODNR01-treated
DIO mice contained signiﬁcantly fewer classically activated pro-
inﬂammatory M1 macrophage cytokines and chemokines
[tumour necrosis factor alpha (TNF-a), IL-1, IP-10 and
monocyte chemoattractant protein (MCP-1)] than did VAT
from PBS-treated orODN1612-treated mice (Fig 5B).In contrast,
neither ODNR01 nor ODN1612 affected alternatively activated
anti-inﬂammatory M2 macrophage cytokines (Arg-1, Mrc-1 and
IL-10; Fig 5C). These observations suggest that ODNR01
regulates M1 macrophage polarization in VAT from DIO mice.
Study of SAT from DIO mice and in VAT and SAT from ob/ob
mice yielded similar observations (Supporting Information
Fig 7). Of note, when cultured naı ¨ve bone marrow-derived
macrophages (BMDMs) were used, neither ODNR01 nor
ODN1612 affected M1 or M2 cytokine and chemokine expres-
sion (Fig 5D), suggesting that ODNR01 affected macrophage
polarization under certain conditions, such as in the presence of
inﬂammation or under activation stimulation from other
inﬂammatory cells or cytokines. To test this hypothesis, we
performed the same experiments as in Fig 5D. Instead of using
naı ¨ve BMDMs, we activated BMDMs with lipopolysaccharide
(LPS, 100ng/ml) and Th1 cytokine IFN-g (100U/ml; Khallou-
Laschetetal,2010).Consistentwithourhypothesis,underthese
conditions,ODNR01showedsigniﬁcantinhibitoryeffects onM1
marker expression, but remained ineffective on M2 marker
expression (Fig 5E). As in CD4
þ T cells (Fig 2C), ODNR01 but
not ODN1612 also interacted with STAT1/3/4, but not with
STAT5/6 in BMDMs. Confocal microscopy demonstrated that
ODNR01 colocalized with STAT1/3/4, but not with STAT5/6 in
BMDMs (Supporting Information Fig 8). Therefore, ODNR01
targets not only T cells, but also macrophages under
inﬂammatory conditions.
Effects of ODNR01 on glucose homeostasis are CD4
R
T-cell-dependent
To examine whether the effects of ODNR01 on controlling
glucose and insulin homeostasis in DIO mice and ob/ob mice
required CD4
þ T cells, we studied T-cell-deﬁcient Rag1-null
(Rag1
 / ) mice, which also gain body weight after consuming a
high-fat diet (HFD; Winer et al, 2009a,b). Rag1
 /  mice at
8 weeks of age started consuming a HFD while receiving
intraperitoneal PBS, ODNR01 or ODN1612 once every other
week. After 18 weeks of a HFD, Rag1
 /  mice receiving PBS or
no treatment (control) gained body weight consistently and
developed type-2diabetes. ODNR01andODN1612 didnot affect
body weight gain (Fig 6A, left panel), glucose tolerance (Fig 6A,
middle panel) or insulin sensitivity (Fig 6A, right panel), unlike
inob/obmiceorDIOWTmice(Fig3DandE).ODNR01therefore
did not improve diabetes in the absence of T cells, suggesting
that ODNR01 activity in improving diabetes is T-cell-dependent.
To test this hypothesis, we adoptively transferred in vitro
preparedCD4
þT cellsfrom WT miceinto Rag1
 / micethathad
consumed 18 weeks of a HFD. At 4 weeks after CD4
þ T-cell
adoptive transfer, we detected donor CD3
þCD4
þ T cells in VAT,
SAT and spleen (Fig 6B). As previously reported (Winer et al,
2009a,b), reconstitution of CD4
þ T cells (PBS group) signiﬁ-
cantly reduced body weight gain (Fig 6C), glucose tolerance,
insulin sensitivity and serum insulin levels (Fig 6D). Although
ODN1612 did not further reduce obesity or improve diabetes
compared to those treated with PBS, ODNR01 further improved
type-2 diabetes signiﬁcantly, including glucose tolerance,
insulin sensitivity and serum insulin levels (Fig 6D). As in
the experiment presented in Fig 3A, ODNR01 did not affect body
weightgain(Fig6C).ConsistentwiththeﬁndingsfromDIOmice
presented in Fig 5B/5C, VAT from Rag1
 /  mice showed
signiﬁcantly reduced expression levels of M1 cytokines and
chemokines (TNF-a, IL-1, IP-10 and MCP-1) after receiving
donor CD4
þ T cells. ODNR01, but not control ODN1612, further
reduced these M1 markers. In contrast, CD4
þ T-cell reconstitu-
tion increased signiﬁcantly all tested M2 markers (Arg-1, Mrc-1
and IL-10) in VAT from Rag1
 /  mice. Neither ODNR01 nor
control ODN1612 further affected the expression of these M2
markers (Supporting Information Fig 9). ODNR01 therefore
improved type 2 diabetes by targeting CD4
þ T cells and
consequentlyM1-cellpolarizationinDIOmiceorob/obmice.To
test this hypothesis further, we reconstituted Rag1
 /  mice that
had consumed 18 weeks of a HFD with CD4
þ T cells that had
been pre-incubated with ODNR01, ODN1612 or vehicle (PBS)
for 3 days. After consuming 4 weeks of a HFD, Rag1
 /  mice
receiving ODNR01-treated CD4
þ T cells demonstrated further
improvement of glucose tolerance, insulin sensitivity and
serum insulin levels compared to non-reconstituted mice or
those receiving PBS-treated or ODN1612-treated CD4
þ T cells
(Fig 6E).
DISCUSSION
Obesityassociates withinﬂammation inadipose tissue.Inﬂux of
macrophages, T cells, mast cells and other untested inﬂamma-
tory cells in adipose tissues releases pro-inﬂammatory media-
tors upon development of chronic caloric excess-driven obesity.
These inﬂammatory cells cause insulin resistance and its
associated complications (Feuerer et al, 2009; Liu et al, 2009;
Nishimura et al, 2009; Winer et al, 2009a; Weisberg et al, 2003).
Immunosuppressive ODNs containing TTAGGG motifs inhibit
the phosphorylation of STAT1/4 and block the differentiation of
Th1 cells and production of their inﬂammatory mediators
(Gursel et al, 2003; Shirota et al, 2004, 2005). This study used
optimized ODNs that replaced the TTAGGG motifs in ODNA151
with TAGGG yielding a potent regulatory ODNR01 that
suppressed Th1/Th17 differentiation and subsequently M1
macrophage polarization, without affecting Th2 and Treg
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regulation of Th1/Th17 versus Th2/Treg as well as impaired
M1 macrophage polarization and recruitment to WAT by
ODNR01 induced protective effects on glucose and insulin
homeostasis in DIO mice and ob/ob mice.
In addition to CD4
þ lymphocytes, many other cell types—
including macrophages (Weisberg et al, 2003), mast cells
(Liu et al, 2009), gdT cells (Zu ´n ˜iga et al, 2010) and eosinophils
(Wu et al, 2011)—also regulate glucose homeostasis. ODNR01
may alleviate insulin resistance through regulating differentia-
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Figure 5. Macrophage accumulation and M1 inflammatory factor expression in VAT from DIO mice treated with or without different ODNs or in vitro
cultured macrophages.
A. Immunostaining of VAT with rat anti-mouse Mac-3 mAb. Graph represents the number of Mac-3
þ cells in each 10 fields.
B-E. RT-PCR determined mRNA levels of (B) M1 markers (TNF-a, IL-6, IP-10 and MCP-1) and (C) M2 markers (Arg1, Mrc1 and IL-10) in VAT after normalizing to
GAPDH. Fold change was calculated relative to PBS group. RT-PCR determined mRNA levels (normalized to GAPDH) of M1 markers (TNF-a, IL-6, IP-10 and
MCP-1) and M2 markers (Arg1, Mrc1 and IL-10) in untreated BMDMs (D) or BMDMs that were stimulated with LPS (10ng/ml) and IFN-g (100U/ml) for 24h
(E), with or without 5mM ODNR01 or ODN1612. Fold change was calculated relative to medium group ( ). Data represent three independent experiments.
 p<0.05;
  p<0.01, n¼4 6.
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to treat lymphocyte-free Rag1-null DIO mice or Rag1-null DIO
mice receiving CD4
þ T-cell adoptive transfer. Our experiments
demonstrated that ODNR01 had no effect on obesity and insulin
resistance in lymphocyte-free Rag1-null DIO mice, while it
improved insulin sensitivity in Rag1-null DIO mice that received
CD4
þ T-cell adoptive transfer suggesting that the beneﬁts of
ODNR01 in obese mice and in WAT are CD4
þ T-cell-dependent.
Obesity and associated type-2 diabetes display a Th1-bias,
based on an existing imbalance in obese WAT between
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Figure 6. CD4
R T-cell-dependent effects of ODNR01 on glucose homeostasis.
A. Rag1
 /  mouse body weight at 8 weeks or after consuming 18 weeks of a HFD along with ODNR01 or ODN1612 treatment (one dose/2 weeks), glucose
tolerance test (GTT) and insulin tolerance test (ITT) at the end of HFD and ODN treatment.
B. FACS plots to detect CD3
þCD4
þ T cells in VAT, SAT and spleen from Rag1
 /  mice that consumed HFD for 18 weeks (no ODN treatments), then received WT
naive CD4
þ T-cell intraperitoneal transfer (5 10
6mouse
 1) at week 26 and consumed HFD for an additional 4 weeks while receiving ODN treatments.
C. Body weight of Rag1
 /  recipients from B.
D. GTT, ITT and serum insulin levels in Rag1
 /  recipients from B.
E. GTT, ITT and serum insulin levels from Rag1
 /  mice that consumed a HFD for 18 weeks (no ODN treatments), received adoptive transfer of in vitro
ODN-treated WT CD4
þ T cells, and consumed a HFD for another 4 weeks. Control: no reconstitution or treatment but HFD for the same time period; PBS:
CD4
þ T-cell-reconstituted mice treated with PBS or mice reconstituted with PBS-treated CD4
þ T cells.
 p<0.05,
  p<0.01, n¼6 8.
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et al, 2009; Nishimura et al, 2009; Rocha et al, 2008; Winer et al,
2009a). A signature Th1 cytokine, IFN-g elevates expression of
MCP-1, TNF-a and RANTES and macrophage accumulation in
obese WAT. Obese IFN-g-deﬁcient animals had decreased
inﬂammatory cell accumulation in WAT and better glucose
tolerance than WT control animals (Rocha et al, 2008) asseen in
ODNR01-treated DIO mice or ob/ob mice (Figs 3D, E, and 5A).
Recent work suggests that Th2 cells exert protective functions in
insulin resistance during obesity (Winer et al, 2009a). Adoptive
transfer of CD4
þT cells to T-cell-deﬁcient Rag1
 /  mice reduced
obesity and improved diabetes (Winer et al, 2009a). The current
study used ODNR01 to regulate the CD4
þ T-cell balance by
blocking Th1- and Th17-cell differentiation. ODNR01 signiﬁ-
cantlyreducedmacrophageaccumulationandM1inﬂammatory
factor expression in WAT and improved glucose and insulin
sensitivity in obese mice. These results suggested that ODNR01
induced protective effects on glucose and insulin homeostasis
in vivo by decreasing Th1-cell functions and enhancing Th2-cell
activities, providing additional evidence that Th1/Th2-cell
counterbalance controls insulin resistance in obese mice. Two
important questions, however, emerged from our observations.
Earlier observations (Winer et al, 2009a) and this study
(Fig 6C) demonstrated that reconstitution of total CD4
þ T cells
reduces body weight gain in Rag1
 /  mice. But inhibition of Th1
andTh17andconcomitant increaseofTh2andTreg byODNR01
in C57BL/6 WT DIO mice, ob/ob mice or CD4
þ T-cell-
reconstituted Rag1
 /  mice did not affect body weight. Reduced
obesity in CD4
þ T-cell-reconstituted Rag1
 /  mice therefore
might not associate with Th2 or Treg, but rather with other
uncharacterized CD4
þ T-cell populations. Previous Treg gain-
of-function and loss-of-function studies (Feuerer et al, 2009)
demonstrated a role of Treg cells in insulin resistance, but the
potential effect of Treg cells on body weight gain had not been
fully studied. Although Winer et al (2009a) demonstrated that
Th2 cells might control body weight gain after CD4
þ T-cell
transfer, recent evidence suggests that Th1 and Th2 cells do not
control body weight gain. In DIO mice, the absence of Th1
cytokine IFN-g led to reductions in WAT macrophages,
adipocyte size and expression of inﬂammatory molecules
(TNF-a and MCP-1). These mice demonstrated increased
glucose sensitivity but showed no difference in body weight
gain compared with WT control mice (Rocha et al, 2008),
suggesting a negligible role of Th1 cells in controlling body
weight. IL-33, a member of the IL-1 family, induces helper
T cells, mast cells and other inﬂammatory cells to produce Th2
cytokines (Schmitz et al, 2005). WAT releases Th2 cytokines
(IL-5, IL-13 and IL-10) after stimulation with IL-33 in vitro
(Miller et al, 2010). In ob/ob mice, administration of
recombinant IL-33 polarized the ATMs toward an M2
alternatively activated phenotype in WAT, reduced WAT
adiposity (reduced adipocyte size and epididymal fat mass)
and improved glucose and insulin tolerance. Activation of Th2
cells, however, did not change body weight gain (Miller et al,
2010). The IFN-g and IL-33 studies support the same conclusion
as the current study: that Th1 or Th2 cells (and possibly Th17 or
Treg cells) may affect WAT inﬂammation, adiposity and glucose
and insulin tolerance, but do not affect body weight gain.
Reduced body weight in CD4
þ T-cell-reconstituted Rag1
 / 
mice (Winer et al, 2009a; Fig 6C) may derive from a different
CD4
þ cell population—a hypothesis that merits further
investigation.
Second, in the current study, inactivation of both Th1 and
Th17 cells improved insulin resistance (Figs 3D, E and 6D
and E). Given the observations from anti-CD3 antibody-treated
DIO micethatdepletionofTh1 cellsordeﬁciency ofTh1 cytokine
IFN-g reversed adipose tissue inﬂammation and insulin resis-
tance (Winer et al, 2009a; Rocha et al, 2008), inactivation of Th1
cells will sufﬁce to improve insulin resistance in ODNR01-treated
mice. Therefore, Th17-cell differentiation may not necessarily
contribute to improved insulin resistance (Figs 3D and E and 6D
and E). We currently do not know the exact role of Th17 cells in
obesity or insulin resistance. Like Th1 cells, Th17 cells
contribute to inﬂammatory autoimmunity (Bettelli et al,
2008), but their possible roles in insulin resistance remains
unclear.ClinicalstudiesrevealedincreasedserumIL-17levelsin
obese patients (Sumarac-Dumanovic et al, 2009), while obesity
selectively promotes Th17-cell lineage expansion, thereby
exacerbating pathogenesis in IL-17-dependent mouse models
of EAE and trinitrobenzene sulphonic acid-induced colitis (Pini
& Fantuzzi, 2010; Winer et al, 2009b). Recent studies also
demonstrate, however, that IL-17 reduces adipogenesis and can
delay the development of obesity (Zu ´n ˜iga et al, 2010). Absence
of IL-17 increases body weight gain in mice. While young adult
IL-17-deﬁcient mice were more sensitive than WT control mice
to glucose and insulin challenges, increased glucose tolerance
and insulin sensitivity in IL-17-deﬁcient mice diminished after
consumption of a HFD for 14–16 weeks (Zu ´n ˜iga et al, 2010).
These observations suggest that IL-17 participates in body
weight gain, but only negligibly contributes to insulin resistance
in mice after consuming a HFD. In the present study, although
ODNR01 decreased Th17 frequencies and IL-17 concentrations
in obese mice, body weight gain did not change among all
groups. Increased body weight gain due to IL-17 inhibition may
have been obscured by reduced overall WAT inﬂammation after
ODNR01 treatment. Further, minimal effects of IL-17 in insulin
resistance in DIO mice (Zu ´n ˜iga et al, 2010) may support a major
role of Th1-cell subsets in type-2 diabetes from the current
study.
This study demonstrated that regulatory ODNR01 limits
immune activation associated with obesity and diabetes. Such
activity of regulatory ODNR01 might beneﬁt humans or animals
with other inﬂammatory diseases, such as cardiovascular
disease, cancers or infectious diseases—a hypothesis that
merits further investigation. But a broad immunosuppressive
activity of ODNR01 or other regulatory ODNs on the overall
immune system, rather than on a speciﬁc tissue (e.g. adipose
tissue), may predispose to opportunistic infections or impair
tumour defenses, although such adverse effects have not
emerged to date. Additional research is needed to determine
whether this compromised immunity of regulatory ODN
outweighs the agent’s therapeutic effect in humans.
Taken together, these results identify an ODN that modulates
mouse WAT inﬂammation and type-2 diabetes by regulating
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macrophage accumulation and M1 inﬂammatory factor expres-
sion in WAT. These resultsafﬁrm the regulatory role of adaptive
immunityinthemetabolicdisordersassociatedwithobesityand
present a potential therapeutic avenue for patients (Klinman
et al, 2009) with, or predisposed to, type-2 diabetes—although
orally available ODNs have not been tested.
MATERIALS AND METHODS
ODNs
Unlabelled, biotin-labelled and FITC-labelled ODNs were synthesized
at Invitrogen, Shanghai, China. All ODNs used in this study were
phosphorothioated (Invitrogen) to prevent degradation (Brown et al,
1994). Sequences of the ODNs used in this study were as follows:
regulatory ODNR01: TAGGGTAGGGTAGGGTAGGG;
regulatory ODNR02: TTTAGGGTTAGGGTTAGGG;
regulatory ODNR03: TCAGGGTCAGGGTCAGGGTCAGGG;
regulatory ODNR04: TAAGGGTAAGGGTAAGGGTAAGGG;
suppressive ODNA151: TTAGGGTTAGGGTTAGGGTTAGGG;
and control ODN1612: GCTAGATGTTAGCGT.
There was no detectable endotoxin or protein contamination in
these ODN preparations.
CD4
R T-cell and macrophage preparation
Peripheral CD4
þ T cells from splenocytes of 8-week-old Th1-biased
C57BL/6 mice and Th2-biased Balb/c mice were MACS-sorted using a
mouse CD4
þ T-cell isolation kit II (Miltenyi Biotec Inc., Auburn, CA),
according to the manufacturer’s instructions. CD4
þ T-cell purity was
confirmed by flow cytometry.
BMDMs were isolated from the femurs and tibias of 8-week-old
C57BL/6 mice and differentiated into macrophages by incubating
bone marrow cells in Iscove’s modified Dulbecco’s medium (IMDM)
supplied with 10% FCS, 1% glutamine and 10ng/ml macrophage-
colony stimulating factor (M-CSF, R&D Systems, Minneapolis, MN), for
7 days as described previously (Odegaard et al, 2007).
Cell culture
To evaluate ODN activities on CD4
þ Tcells, CD4
þ Tcells (2.5 10
6/ml)
were cultured in a complete medium (RPMI 1640 medium and 10%
foetal bovine serum) in the presence of plate-bound anti-CD3
(1mg/ml) and soluble anti-CD28 (1mg/ml) monoclonal antibodies
(mAb, BD Pharmingen, San Diego, CA) to activate T-cell receptors
(TCRs). Th1 mixture [IL-12 (10ng/ml) and anti-IL-4 antibody
(10mg/ml)] or Th17 mixture [IL-6 (20ng/ml), TGF-b (3ng/ml), IL-23
(10ng/ml), anti-IFN-g and anti-IL-4 antibodies (10mg/ml)] were
added to drive Th1 and Th17 polarization, respectively. Cells were
cultured with or without different concentrations of ODNs for 3 days.
After brief washes, 2 10
6ml
 1 viable cells were re-stimulated with
1mg/ml plate-bound anti-CD3 mAb for another 48h. Culture super-
natants were collected and stored at  808C for cytokine ELISA
analysis. In some experiments, cells after 3–4 days of treatment with
ODNs were used for RT-PCR, flow cytometric analysis or mouse
adoptive transfer.
To evaluate the effect of ODNR01 on BMDM differentiation, we
stimulated BMDMs with ODNR01 (5mM) or ODN1612 (5mM) for 48h
(Baek et al, 2001), purified total RNA using Trizol (Invitrogen, Carlsbad,
CA) and determined relative mRNA levels using RT-PCR. To study the
effects of ODNs on CD4
þ T-cell differentiation signal pathways, anti-
CD3/28 mAb-stimulated CD4
þ T cells were incubated with different
stimuli (e.g. IFN-g, IL-12, IL-2 and IL-4), washed with PBS, and lysed in
ice-cold PhosStop lysis buffer containing protease and phosphatase
inhibitors (Roche Applied Science, Indianapolis, IN). Protein extracts
were used for Western blot analysis.
Confocal microscopy
CD4
þ T cells or BMDMs were incubated with FITC-labelled ODN
(2.5mM) for 24h at 378C in a complete RPMI 1640 medium
containing 10% foetal bovine serum (CD4
þ T cells) or DMEM
containing 5% foetal bovine serum (BMDMs). Cells were washed
and fixed with 4% paraformaldehyde, permeabilized with 1% Triton-
100 in PBS, and stained with rabbit anti-STAT1/3/4/5/6 antibodies
(1mg/ml, Signalway Antibody, Pearland,TX), followed by Alex Fluor 555
or 670-labelled anti-rabbit antibody. The cells were analyzed with
confocal microscopy for subcellular localization of FITC and Alex Fluor
555 or 670 (Nikon A1Si; Nikon instruments, Japan).
Ligand binding studies
CD4
þ T cells were incubated for 4h with 5mM biotinylated-ODN
at 378C before lysis, and subjected to microcentrifugation to
remove nuclear debris. Alternatively, clarified cellular lysates
were incubated with 1mM biotinylated-ODN and 5mM free ODN
for 2h at 48C. Twenty-five microliters of avidin-coated agarose
(Sigma–Aldrich, St. Louis, MO) were added to 200ml of lysate and
rotated for 30min at 48C. Pellets were washed four times in lysis
buffer, boiled for 10min, and then analyzed by Western blot
(Latz et al, 2004).
Mice
Wild-type C57BL/6 mice, genetically generated obese (ob/ob) mice,
and Rag1-deficient (Rag1
 / ) mice were purchased from the Jackson
Laboratories (Bar Harbor, ME). Regulatory ODNR01 and non-specific
control ODN1612 were dissolved in 300ml PBS for intraperitoneal
injection once every 2 weeks. Eight-week-old mice received either a
normal chow diet (NCD) or a HFD (D12492, Research Diets, Inc., New
Brunswick, NJ) for 10 weeks (ob/ob mice, NCD), 14 weeks (C57BL/6
mice, HFD) or 22 weeks (Rag1
 /  mice, HFD). ODNs at 12mg/kg body
weight were given to C57BL/6 mice, Rag1
 /  mice and ob/ob mice. For
CD4
þ T-cell reconstitution experiments, 8-week-old Rag1
 /  mice
consumed a HFD for 18 weeks and then received CD4
þ T cells
(5 10
6mouse
 1) or CD4
þ T cells pre-incubated with ODNR01
(5mM), ODN1612(5mM) or no ODN (5 10
6mouse
 1). Mice
continued on a HFD for four more weeks before characterization.
The Harvard Medical School Standing Committee on Animals
approved all animal experiments.
Body weight was monitored weekly. Glucose tolerance tests (GTTs) and
insulin tolerance tests (ITTs) were conducted in mice before adoptive
transfer and at sacrifice. For GTTs, we gave fasted (16h) mice 1g of
glucose/kg body weight; for ITTs, we gave 0.75U/kg body weight of
human regular insulin (Novo Nordisk, Bagsværd, Danmark; 2U/kg in
ob/ob mice).
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cytometry analysis
We isolated SVF using previously described methods, with some
modifications (Rocha et al, 2008). Epididymal VAT and SAT were
removed and minced into small pieces ( 2mm) in cold PBS. Tissues
were digested in RPMI-1640 containing 35mg/ml Liberase TM (Roche
Applied Science) and 50U/ml DNase I (Sigma) at 378C for 45min.
Digested tissues were passed through a 70-mm cell strainer (BD
Biosciences) and flow-through centrifuged. After aspirating the
supernatant, red blood cells were lysed with an ACK lysing buffer
(Gibco). The remaining cells, as SVF, were washed with RPMI-1640
twice and used for flow cytometry or CD4
þ T-cell sorting. Splenocytes
were isolated as previously described (Cheng et al, 2008).
The following antibodies were used for flow cytometry: anti-CD3-APC,
anti-CD4-FITC, anti-IFN-g-PE, anti-IL-17-PE-cy7, anti-IL-4-APC and
anti-Foxp3-APC (all from eBioscience, Inc., San Diego, CA). For surface
staining, cells were incubated with antibodies for 20min at 48C. For
Treg staining, cells were fixed and permeabilized according to the
manufacturer’s instructions (eBioscience, Inc.) before adding the anti-
Foxp3 antibody. For the Th1, Th2 and Th17 staining, cells were re-
stimulated with 50ng/ml phorbol 12-myristate 13-acetate (PMA) and
500ng/ml ionomycin in the presence of GolgiPlug for 6h, fixed, and
permeabilized before adding anti-IFN-g, IL-4 or IL-17 antibodies.
Isotype controls were used to correct compensation and to confirm
antibody specificity. All samples were analyzed using flow cytometry
on a FACSCalibur (BD Biosciences).
Immunohistochemistry
Visceral adipose tissue was fixed and embedded in paraffin. Section
staining was performed with a rat anti-mouse Mac-3 mAb (1:900, BD
Pharmingen) as described previously (Liu et al, 2009). Positive cells were
counted in 10 consecutive visual fields at the same magnification.
Real-time PCR
Total RNAs from CD4
þ T cells, BMDMs and adipose tissues were
prepared using a TRIzol reagent (Invitrogen). IFN-g, IL-17, IL-4, T-bet,
RORgt, GATA-3, Foxp3, TNF-a, IL-6, interferon-inducible protein (IP)-
10, MCP-1, arginase 1 (Arg1), mannose receptor C-type 1 (Mrc1), IL-10
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA
templates were synthesized using a random hexamer primer and
RNase H-reverse transcriptase (Invitrogen). RT-PCR was performed and
analyzed on an ABI Prism 7900 Sequence Detection system (Applied
Biosystems, Carlsbad, CA) using SYBR Green Master Mix (Takara,
Madison, WI). The relative expression level of each gene was
normalized with housekeeping gene GAPDH and calculated by the
2
 DDCt methods.
Western blotting
Protein extracts from CD4
þ Tcells were used for Western blots. Lysate
protein concentrations were determined using a BCA protein kit
(Pierce, Rockford, IL). Protein extract (25mg) from each sample was
separated on a 9% sodium dodecyl sulphate–polyacrylamide gel
electrophoresis (SDS–PAGE) for Western blot analysis. Western blots
were probed using primary antibodies to phosphorylated-STAT1,
STAT3, STAT4, STAT5, STAT6 and corresponding non-phosphorylated
STATs (all at 1:1000 dilution; Cell Signaling Technology, Inc., Danvers,
MA). Horseradish peroxidase-conjugated anti-rabbit IgG (1:20,000,
Sigma) was used as a secondary antibody. Proteins were detected
using an ECL detection kit (Pierce). A comparative analysis was
performed using quantitative densitometry.
ELISA
The concentrations of IFN-g, IL-4, IL-17 and insulin in CD4
þ T-cell
culture media or mouse serum were measured by enzyme-linked
immunosorbent assay (ELISA) according to the manufacturer’s
instructions (cytokines, R&D Systems; insulin, LINCO Research, Inc.,
St. Charles, MO). All assays were performed in triplicate.
Statistics
Data were expressed as mean SEM. One-way analysis of variance
(ANOVA), followed by post-hoc SNK test, was used for comparisons
between groups. p<0.05 was considered statistically significant.
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The paper explained
PROBLEM:
Regulatory ODNs may be used to suppress pro-inflammatory
T-cell subsets, thereby improving body weight gain, glucose
metabolism and insulin sensitivity in obese subjects.
RESULTS:
This study developed a novel, non-toxic and potent immuno-
suppressive regulatory ODN afterscreening ofa setof newODNs,
based on structural modifications of existing ODNs. This new
ODN can selectively block pro-inflammatory T cells (Th1 and
Th17) by binding and inactivating the essential STAT signalling
pathways of Th1 and Th17, without affecting those of anti-
inflammatory T-cell subsets (Th2 and regulatory T cells). In both
diet-induced and genetically modified obese mice, this new ODN
enhanced glucose metabolism and insulin sensitivity and
suppressed adipose tissue inflammation, including reduced
adipose tissue fat cell size and impaired pro-inflammatory
macrophage accumulation and polarization. These ODN phe-
notypes disappeared in T-cell-deficient mice, but reappeared
after mice received T-cell-adoptive transfer—and therefore are
T-cell-dependent.
IMPACT:
As immunostimulatory ODN has been used in several clinical
trials in cancer patients, this immunosuppressive ODN may have
therapeutic potential in patients with obesity, diabetes and
associated complications.
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